Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Marinus Pharmaceuticals, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from March 17, 2021, to May 7, 2024 [1][2]. Group 1: Allegations - The complaint alleges that Marinus Pharmaceuticals understated the risk of failing to meet early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE) [1]. - It is claimed that the company did not disclose that failing to meet the early stopping criteria in the RAISE trial could lead to the cessation of the separate Phase 3 RAISE II trial [1]. - As a result, the statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading, lacking a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased shares of MRNS during the specified class period are encouraged to register for the class action, with a deadline set for August 5, 2024 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. - There is no cost or obligation for shareholders to participate in this case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who incurred losses due to false or misleading statements or omissions of material information that led to artificial inflation of the company's stock [3].